Mitsubishi UFJ Asset Management UK Ltd. Acquires 3,000 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Mitsubishi UFJ Asset Management UK Ltd. raised its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 12.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,000 shares of the specialty pharmaceutical company’s stock after buying an additional 3,000 shares during the quarter. Mitsubishi UFJ Asset Management UK Ltd.’s holdings in Supernus Pharmaceuticals were worth $976,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. GAMMA Investing LLC grew its stake in Supernus Pharmaceuticals by 97.1% during the third quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock valued at $25,000 after acquiring an additional 398 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Supernus Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock worth $61,000 after purchasing an additional 352 shares during the last quarter. Kennebec Savings Bank purchased a new stake in shares of Supernus Pharmaceuticals in the third quarter worth about $103,000. Quest Partners LLC bought a new position in Supernus Pharmaceuticals during the third quarter valued at approximately $241,000. Finally, HighTower Advisors LLC purchased a new position in Supernus Pharmaceuticals during the 3rd quarter valued at approximately $264,000.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, Director Georges Gemayel sold 14,213 shares of the business’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $36.62, for a total value of $520,480.06. Following the completion of the sale, the director now directly owns 13,315 shares of the company’s stock, valued at $487,595.30. The trade was a 51.63 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Frank Mottola sold 15,000 shares of the company’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $36.98, for a total transaction of $554,700.00. Following the completion of the transaction, the senior vice president now owns 8,200 shares in the company, valued at $303,236. This represents a 64.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 154,213 shares of company stock worth $5,660,180. 9.30% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several brokerages recently weighed in on SUPN. Cantor Fitzgerald began coverage on shares of Supernus Pharmaceuticals in a research report on Monday, January 6th. They issued an “overweight” rating and a $57.00 price target on the stock. Cowen reaffirmed a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Finally, Piper Sandler reissued a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

Supernus Pharmaceuticals Stock Up 2.2 %

SUPN stock opened at $38.58 on Wednesday. Supernus Pharmaceuticals, Inc. has a twelve month low of $25.53 and a twelve month high of $39.37. The stock has a market capitalization of $2.13 billion, a price-to-earnings ratio of 36.06 and a beta of 0.90. The firm’s fifty day simple moving average is $36.71 and its two-hundred day simple moving average is $33.93.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.44 by $0.25. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The company had revenue of $175.70 million for the quarter, compared to the consensus estimate of $157.35 million. During the same period in the prior year, the firm posted ($0.29) EPS. The firm’s revenue was up 14.2% compared to the same quarter last year. As a group, equities research analysts expect that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.